文献速递肝病消化道出血消化内镜

既往失代偿可识别静脉曲张出血后标准治疗下高死亡风险患者:个体患者数据荟萃分析

Prior Decompensation Identifies Patients at High Mortality Risk Despite Standard Therapy After Variceal Hemorrhage: An Individual Patient Data Meta-Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-07-22

本研究为系统综述和个体参与者数据荟萃分析,纳入13项研究共1659例Child-Pugh A-B级肝硬化静脉曲张出血患者,均接受非选择性β受体阻滞剂联合内镜下静脉曲张套扎术预防再出血。既往失代偿与死亡风险升高独立相关(汇总校正HR 1.4,95%CI 1.1-1.7),新发或加重失代偿风险亦显著升高(汇总校正HR 1.7,95%CI 1.15-2.44)。

要点

  • Child-Pugh A-B级肝硬化静脉曲张出血后标准治疗患者中,有既往失代偿者2年死亡率为25.1%。
  • 既往失代偿与死亡风险独立相关,汇总校正HR为1.4(95%CI 1.1-1.7)。
  • 既往失代偿者新发或加重失代偿风险亦显著升高,汇总校正HR为1.7(95%CI 1.15-2.44)。

核心结论

  • 在Child-Pugh A-B级肝硬化、不适合抢先TIPS且接受非选择性β受体阻滞剂联合套扎术预防再出血的患者中,既往失代偿可识别死亡风险升高的亚组。

研究设计与样本

  • 系统综述与个体参与者数据荟萃分析,纳入13项研究(5项随机对照试验,8项观察性研究),共1659例患者。
  • 纳入患者为肝硬化静脉曲张出血、不符合抢先TIPS条件、接受非选择性β受体阻滞剂联合内镜下静脉曲张套扎术预防再出血者。
  • 采用病因特异性Cox模型和随机效应个体参与者数据荟萃分析评估全因死亡和新发或加重失代偿。

主要发现

  • 1659例患者中Child-Pugh A级805例、B级853例;606例有既往失代偿,121例有腹水,154例有肝性脑病(单独或合并),106例有腹水加静脉曲张出血,225例仅有静脉曲张出血。
  • 特定校正风险比:既往腹水1.8(95%CI 1.2-2.6),肝性脑病1.7(95%CI 1.3-2.3),静脉曲张出血0.83(95%CI 0.6-1.2),静脉曲张出血加腹水1.4(95%CI 0.92-2.3)。
  • 个体参与者数据荟萃分析显示,既往失代偿者死亡的汇总校正HR为1.4(95%CI 1.1-1.7)。
  • 任何既往失代偿者新发或加重失代偿的汇总校正HR为1.7(95%CI 1.15-2.44)。

临床怎么用

  • 对于Child-Pugh A-B级肝硬化静脉曲张出血后接受标准二级预防的患者,应评估既往失代偿事件以识别高死亡风险亚组。
  • 既往失代偿患者死亡和新发或加重失代偿风险较高,TIPS的潜在获益值得进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In patients with variceal hemorrhage, nonselective beta-blockers plus endoscopic variceal ligation are recommended to prevent rebleeding when pre-emptive transjugular intrahepatic portosystemic shunt is not indicated or placed. The aim of this study was to determine whether decompensating events occurring before variceal hemorrhage are associated with worse outcomes in patients treated with nonselective beta-blockers plus endoscopic variceal ligation to prevent recurrent variceal hemorrhage. METHODS: This was a systematic review and individual participant data meta-analysis of studies including patients with cirrhosis and variceal hemorrhage not eligible for pre-emptive transjugular intrahepatic portosystemic shunt in patients with Child-Pugh class A-B and receiving nonselective beta-blockers plus endoscopic variceal ligation to prevent recurrent bleeding. All-cause mortality and new or worsening decompensation were analyzed using cause-specific Cox models and random-effects individual participant data meta-analysis. RESULTS: Thirteen studies (5 randomized controlled trials, 8 observational) contributed 1659 patients (Child-Pugh class A, 805; class B, 853); 606 had had prior decompensation, 121 had ascites, 154 had encephalopathy (alone or combined), 106 had ascites plus variceal hemorrhage, and 225 had variceal hemorrhage alone. The 2-year mortality was 25.1% with prior decompensation and 13.5% without (P < .0001): specific adjusted hazard ratios were 1.8 (95% confidence interval, 1.2-2.6) for prior ascites, 1.7 (95% confidence interval, 1.3-2.3) for encephalopathy, 0.83 (95% confidence interval, 0.6-1.2) for variceal hemorrhage, and 1.4 (95% confidence interval, 0.92-2.3) for variceal hemorrhage + ascites. Individual patient data meta-analysis showed a pooled adjusted hazard ratio for death of 1.4 (95% confidence interval, 1.1-1.7) with prior decompensation. New or worsening decompensation was also significantly higher with any prior decompensation: pooled adjusted hazard ratio, 1.7 (95% confidence interval, 1.15-2.44). CONCLUSIONS: Among patients with Child-Pugh class A-B cirrhosis who were not candidates for pre-emptive transjugular intrahepatic portosystemic shunt and were treated with nonselective beta-blockers plus endoscopic variceal ligation after variceal hemorrhage, prior decompensation identified a subgroup at increased risk of mortality in whom the potential benefit of transjugular intrahepatic portosystemic shunt warrants further investigation.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Turco L, La Mura V, Olivas P, et al. Prior Decompensation Identifies Patients at High Mortality Risk Despite Standard Therapy After Variceal Hemorrhage: An Individual Patient Data Meta-Analysis. Clin Gastroenterol Hepatol. 2026. PMID: 42486395. doi:10.1016/j.cgh.2026.07.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。